Home » Posts tagged 'Rare orphan drugs'
Tag Archives: Rare orphan drugs
Open Orphan (ORPH) CEO Cathal Friel tells Alan Green why he expects 40 percent growth year on year.
Open Orphan (ORPH) currently trades on just 1x revenues & a market cap of just £15m. CEO Cathal Friel tells Alan Green why he expects to see his company, into which he’s invested £2m of his own cash, grow by some 40% year on year, reach a market cap of some £50m and pay a dividend to investors in year 2. Cathal also discusses the high margins the business model will throw off, the wealth of talent now on the Open Orphan board, plus he provides key takeaway points for investors.